Actively Recruiting
Optimized Umbilical Cord Blood Transplantation with Chemotherapy and Total-Body Irradiation for Adults and Children with High-Risk Blood Cancers
Led by Fred Hutchinson Cancer Center · Updated on 2026-10-26
54
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well an umbilical cord blood transplant combined with chemotherapy drugs cyclophosphamide, fludarabine, and total-body irradiation TBI works in treating patients with high-risk hematologic diseases. The trial focuses on patients with various blood cancers and disorders, aiming to stop cancer growth and prevent rejection of donor stem cells. This phase II trial also studies how cyclosporine and mycophenolate mofetil may prevent immune reactions against the patients normal cells after the transplant. Participants are assigned to one of two treatment arms based on age. Arm I includes patients aged 6 months to 30 years who receive fludarabine, cyclophosphamide, and high-dose TBI before undergoing umbilical cord blood transplantation UCBT. Arm II includes patients aged 6 months to 65 years who receive fludarabine, cyclophosphamide, thiotepa, and middle-intensity TBI before UCBT. After transplant, all patients receive medications cyclosporine and mycophenolate mofetil to reduce the risk of graft-versus-host disease GVHD with specific dosing schedules and tapering plans. Throughout the study, participants undergo blood sample collections, bone marrow aspirates, echocardiography or multigated acquisition scans, and diagnostic imaging during screening and as needed. Follow-up visits occur at day 180, 1 year, and 2 years to monitor overall survival and other outcomes like engraftment, graft failure, incidence of GVHD, adverse events, immunosuppression cessation, and transplant-related mortality. The study evaluates these measures up to 3 years after transplantation to assess treatment effects and safety.
CONDITIONS
Brief Title
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Research Team
A
Ann Dahlberg
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here